贝伐单抗联合FOLFIRIl方案治疗转移性结直肠癌的研究进展[J].pdfVIP

肿瘤2013 年6 月第33 卷第6 期　TUM OR Vol. 33, J une 2013　　 571 DOI: 10.3781/j .issn.1000-7431.2013.06.016 Copyright© 2013 by TUM OR Review 综述 · 贝伐单抗联合FOLFIRI方案治疗转移性结直肠癌的研究进展 郑　铎，吕　超，吴玉立，吴硕东 中国医科大学附属盛京医院胆道血管外科，辽宁沈阳　110004 [ 摘要 ]　结直肠癌（colorectal cancer ，CRC ）是常见的恶性肿瘤，近年来其发病率呈明显上升趋势。以FOLFIRI （氟 尿嘧啶、亚叶酸钙和伊立替康）为主的细胞毒性化疗方案对CRC 的治疗有显著疗效。贝伐单抗是美国食品药品管 理局 （Food and Drug Administration ，FDA ）批准的一线治疗CRC 的重组人源化单克隆抗体，其以血管内皮生长 因子 （vascular endothelial growth factor ，VEGF ）为靶点，能特异性抑制肿瘤组织血管生成，从而抑制肿瘤组织生 长和肿瘤细胞血行转移。本文对贝伐单抗联合标准化疗方案FOLFIRI 治疗转移性结直肠癌 （metastatic colorectal cancer ，mCRC ）的疗效和安全性进行简要综述。 [ 关键词 ]　结直肠肿瘤；药物疗法，联合；血管内皮生长因子类；贝伐单抗 [中图分类号]　R735.3 [文献标志码] A [文章编号]　1000-7431 (2013) 06-0571-04 Advances in bevacizumab combining with FOLFIRI regimen in treament of metastatic colorectal cancer ZHENG Duo, LÜ Chao, WU Yu-li, WU Shuo-dong Department of Biliary and Vascular Surgery, Affiliated Shengjing Hospital, China Medical University, Shenyang 110004, Liaoning Province, China [A BSTRACT]　CRC (colorectal cancer) is one of the most common malignant tumors, with an upward trend in incidence rate in recent decades. FOLFIRI regimen (fluorouracil + leucovorin + irinotecan) as a cytotoxic chemotherapy regimen for patients with CRC has an obvious efficacy. Bevacizumab is a recombinant humanised monoclonal antibody, which was approved by American FDA (Food and Drug Administration) of the United States and used as the first-line treament for CRC. Bevacizumab which is tageting VEGF (vascular endothelial growth factor) can paticularly inhibit angiogenesis in tumor tissues and inhibit the growth and metastasis of tumor cells. This review summarizes the efficacy and safety of bevacizumab in combination with standard chemotherapy regimen FOLFIRI for patie